BACKGROUND: To clarify the tolerance and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer. METHODS: From January 2008 through to September 2009, combined therapy with S-1 and trastuzumab was given to 7 patients with HER2-positive metastatic or recurrent breast cancer. The incidence of adverse events and the pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil in plasma were studied. RESULTS: One patient had grade 3 leukopenia, and another had a grade 3 elevation of alanine aminotransferase. All other adverse events were grade 2 or lower. The combination of S-1 and trastuzumab did not cause any new adverse events. The incidence of adverse events was similar to those associated with S-1 alone. The median number of treatment cycles was 11. The pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil after treatment with S-1 plus trastuzumab did not markedly differ from those after S-1 alone. CONCLUSIONS: Combined therapy with S-1 and trastuzumab did not cause any new adverse events, administration continuity was good, and the therapy was well tolerated.
BACKGROUND: To clarify the tolerance and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with humanepidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer. METHODS: From January 2008 through to September 2009, combined therapy with S-1 and trastuzumab was given to 7patients with HER2-positive metastatic or recurrent breast cancer. The incidence of adverse events and the pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil in plasma were studied. RESULTS: One patient had grade 3 leukopenia, and another had a grade 3 elevation of alanine aminotransferase. All other adverse events were grade 2 or lower. The combination of S-1 and trastuzumab did not cause any new adverse events. The incidence of adverse events was similar to those associated with S-1 alone. The median number of treatment cycles was 11. The pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil after treatment with S-1 plus trastuzumab did not markedly differ from those after S-1 alone. CONCLUSIONS: Combined therapy with S-1 and trastuzumab did not cause any new adverse events, administration continuity was good, and the therapy was well tolerated.
Authors: B L Tranum; B McDonald; T Thigpen; C Vaughn; H Wilson; T Maloney; J Costanzi; J Bickers; N G el Mawli; R Palmer; B Hoogstraten; L Heilburn; S Rasmusen Journal: Cancer Date: 1982-03-01 Impact factor: 6.860
Authors: Carolyn D Britten; Richard S Finn; Linda D Bosserman; Steven G Wong; Michael F Press; Mubashira Malik; Bert L Lum; Dennis J Slamon Journal: Clin Breast Cancer Date: 2009-02 Impact factor: 3.225
Authors: Ralph G Zinner; Bonnie S Glisson; Frank V Fossella; Katherine M W Pisters; Merril S Kies; Pamela M Lee; Erminia Massarelli; Bradley Sabloff; Herbert A Fritsche; Jae Y Ro; Nelson G Ordonez; Hai T Tran; Ying Yang; Terry L Smith; Robert D Mass; Roy S Herbst Journal: Lung Cancer Date: 2004-04 Impact factor: 5.705
Authors: T Taguchi; K Morimoto; N Horikoshi; S Takashima; T Toge; M Kimura; M Sano; H Aoyama; J Ota; S Noguchi Journal: Gan To Kagaku Ryoho Date: 1998-06